Wilson Disease Pipeline, Clinical Trials Assessment 2023 (Updated) | Companies - Alexion Pharmaceuticals, Vivet Therapeutics, Orphalan, Ultragenyx Pharmaceutical, Nobelpharma, and Others

DelveInsight, a leading market research and consulting firm, has recently published an in-depth report on the Wilson Disease pipeline, providing valuable insights into emerging therapies, companies, and future outlooks.

DelveInsight's, "Wilson Disease Pipeline Insight 2023" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in the Wilson Disease pipeline landscape. It covers the Wilson Disease pipeline drug profiles, including Wilson Disease clinical trials and nonclinical stage products. It also covers the Wilson Disease therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

To explore more information on the latest breakthroughs in the Wilson Disease Pipeline treatment landscape of the report, click here @ Wilson Disease Pipeline Outlook- https://www.delveinsight.com/report-store/wilson-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Wilson Disease Pipeline Report
• DelveInsight's Wilson Disease Pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Wilson Disease.
• The leading Wilson Disease Companies include Alexion Pharmaceuticals, Vivet Therapeutics, Orphalan, Ultragenyx Pharmaceutical, Nobelpharma, and others
• Promising Wilson Disease Pipeline Therapies include Zinc acetate, NPC-02, Penicillamine (D1-W12), ALXN1840, and others.
• On April, 2023, the launch of CUVRIOR to treat stable Wilson disease in adults who are de-copped and able to take penicillamine is being recognised by PANTHERx® Rare, a pioneer in the U.S. market for rare illness products and patient access and support services.
• The Wilson Disease pipeline report provides an extensive analysis of the emerging therapies in the Wilson Disease pipeline, including their mechanism of action, clinical development stage, and ongoing clinical trials. It sheds light on several innovative approaches, such as gene therapies, chelators, and ATP7B modulators, which aim to address the underlying cause of the disease and improve patient outcomes.
• Wilson Disease Pipeline provides detailed information about its pipeline products, strategic collaborations, licensing agreements, and recent developments. The Wilson Disease report provides valuable insights into the future prospects of the Wilson Disease market. It discusses the potential commercialization of pipeline therapies and their impact on the treatment landscape.

For further information, refer to the detailed Wilson Disease Unmet Needs, Wilson Disease Market Drivers, and Wilson Disease Market Barriers, click here for Wilson Disease Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/wilson-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Wilson Disease Overview
Wilson disease is a rare genetic disorder characterized by excess copper stored in various body tissues, particularly the liver, brain, and corneas of the eyes. The disease is progressive and, if left untreated, it may cause liver (hepatic) disease, central nervous system dysfunction, and death. Common signs of associated liver disease include a yellow discoloration (jaundice) of the skin, mucous membranes and the membranes (sclera) that line the eye, swelling (edema) of the legs and abdomen (ascites).

Request a sample and discover the recent advances in Wilson Disease Ongoing Clinical Trial Analysis and Medications, click here @ Wilson Disease Treatment Landscape- https://www.delveinsight.com/sample-request/wilson-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Wilson Disease Emerging Drugs Profile

• ALXN1840: Alexion Pharmaceuticals
ALXN1840 (bis-choline tetrathiomolybdate) is a novel oral copper-protein binding agent with a unique mechanism of action, under investigation for Wilson disease, a rare, chronic, genetic, and potentially life-threatening liver disorder of impaired copper transport. Enrollment of participants have been completed in a Phase 3 study of ALXN1840 in Wilson disease. The study results are expected in the first half of 2022.

• TETA 4HCL: Orphalan
Triethylenetatramine (TETA) is a highly selective divalent Cu(II) chelator and a drug that revereses copper overload in tissues. Trientine is a copper chelator used in the treatment of Wilson's disease as an alternative to D-penicillamine. Clinical trials for TETA 4HCL are being carried out in phase III stage of development for the treatment of Wilsons disease.

Dive deep into rich insights for drugs for Wilson Disease Market Drivers and Wilson Disease Market Barriers, click here @ Wilson Disease Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/wilson-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Wilson Disease Pipeline Therapeutics Assessment
There are approx. 5+ key companies which are developing the therapies for Wilson Disease. The companies which have their Wilson Disease drug candidates in the most advanced stage, i.e. phase III include, Alexion Pharmaceuticals.

Scope of the Wilson Disease Pipeline Report
• Coverage- Global
• Wilson Disease Companies- Alexion Pharmaceuticals, Vivet Therapeutics, Orphalan, Ultragenyx Pharmaceutical, Nobelpharma, and others
• Wilson Disease Pipeline Therapies- Zinc acetate, NPC-02, Penicillamine (D1-W12), ALXN1840, and others.
• Wilson Disease Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

Got Queries? Find out the related information on Wilson Disease Mergers and acquisitions, Wilson Disease Licensing Activities @ Wilson Disease Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/wilson-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Wilson Disease: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Wilson Disease - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Wilson Disease Collaboration Deals
9. Late Stage Products (Preregistration)
10. ALXN1840: Alexion Pharmaceuticals
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. Bis-Choline Tetrathiomolybdate: Alexion Pharmaceuticals
14. Drug profiles in the detailed report…..
15. Early Stage Products (Phase I)
16. VTX-801: Vivet Therapeutics
17. Drug profiles in the detailed report…..
18. Preclinical Stage Products
19. Drug Name: Company name
20. Drug profiles in the detailed report…..
21. Inactive Products
22. Wilson Disease Key Companies
23. Wilson Disease Key Products
24. Wilson Disease- Unmet Needs
25. Wilson Disease- Market Drivers and Barriers
26. Wilson Disease- Future Perspectives and Conclusion
27. Wilson Disease Analyst Views
28. Wilson Disease Key Companies
29. Appendix

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services

This release was published on openPR.